Bleximenib for Acute Myeloid Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called bleximenib for adults with acute myeloid leukemia (AML). The researchers aim to determine if adding bleximenib to standard chemotherapy can improve outcomes for patients whose leukemia cells have specific genetic changes. Participants will receive either bleximenib or a placebo (a harmless sugar pill) along with chemotherapy, and neither they nor their doctors will know which one they are receiving. The trial seeks individuals recently diagnosed with AML who have mutations in the NPM1 or KMT2A genes and can undergo intensive chemotherapy. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants a chance to contribute to a treatment that could soon become widely available.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that bleximenib, a drug tested for treating acute myeloid leukemia (AML), appears safe. In earlier studies, patients tolerated bleximenib well when combined with the standard '7+3' chemotherapy, experiencing no unexpected or severe side effects beyond the usual for this treatment.
Other studies have also tested bleximenib's safety with different AML treatments. At the recommended dose, patients with relapsed or hard-to-treat AML responded well, with most not experiencing severe side effects.
These findings suggest that bleximenib is generally safe for AML patients, particularly those with certain genetic changes. However, individual responses can vary, and ongoing studies continue to monitor safety closely.12345Why do researchers think this study treatment might be promising for AML?
Researchers are excited about Bleximenib for treating Acute Myeloid Leukemia (AML) because it offers a novel approach compared to current therapies. Unlike traditional chemotherapy, which broadly targets rapidly dividing cells, Bleximenib specifically inhibits certain proteins involved in cancer cell growth and survival, potentially leading to more effective and targeted treatment with fewer side effects. Additionally, Bleximenib is being studied not only in combination with standard remission induction and consolidation therapies but also as a maintenance therapy, which could help sustain remission longer than current options. This dual approach could represent a significant advancement in managing AML more effectively over time.
What evidence suggests that bleximenib could be an effective treatment for acute myeloid leukemia?
Research has shown that bleximenib effectively targets acute myeloid leukemia (AML) cells with specific gene mutations. In earlier studies, patients with AML who had mutations in the NPM1 or KMT2A genes experienced a 95.8% overall response rate when treated with bleximenib and standard chemotherapy, meaning almost all patients saw a reduction in cancer cells. In this trial, participants in Arm 1 will receive standard care plus bleximenib, followed by maintenance treatment with bleximenib. Participants in Arm 2 will receive standard care plus bleximenib, followed by maintenance treatment with a placebo. Arm 3 will involve standard care plus a placebo, followed by maintenance treatment with a placebo. The treatment disrupts a key process in leukemia cells, causing them to die. These encouraging results suggest that bleximenib could improve outcomes for patients with these specific genetic changes in their leukemia.13678
Who Is on the Research Team?
M.H.G.P. Raaijmakers
Principal Investigator
Erasmus Medical Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Induction and Consolidation Therapy
Participants receive standard chemotherapy treatment combined with either bleximenib or placebo
Maintenance Therapy
Participants receive maintenance therapy with either bleximenib or placebo until disease progression or unacceptable toxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Bleximenib
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
Bleximenib in combination with remission induction and consolidation therapy, followed by placebo maintenance therapy. Treatment will continue until PD, unacceptable toxicity or other protocol defined criteria for discontinuation (whichever comes first)
Bleximenib in combination with remission induction and consolidation therapy, followed by bleximenib maintenance therapy. Treatment will continue until PD, unacceptable toxicity or other protocol defined criteria for discontinuation (whichever comes first)
Placebo comparator in combination with remission induction and consolidation therapy, followed by placebo maintenance therapy . Treatment will continue until PD, unacceptable toxicity or other protocol defined criteria for discontinuation (whichever comes first)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stichting Hemato-Oncologie voor Volwassenen Nederland
Lead Sponsor
German-Austrian Acute Myeloid Leukemia Study Group
Collaborator
Citations
Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617 ...
The novel inhibitor JNJ-75276617 (bleximenib) targets the menin-KMT2A interaction and has shown preclinical efficacy in AML.
2.
ashpublications.org
ashpublications.org/blood/article/146/Supplement%201/5199/555541/Bleximenib-in-combination-with-intensiveA phase 1b study in newly diagnosed Acute Myeloid ...
The intention-to-treat efficacy dataset comprises pts with NPM1m or KMT2Ar who received bleximenib 100 mg BID in combination with '7+3', ...
3.
bloodcancerstoday.com
bloodcancerstoday.com/post/promising-phase-1b-results-set-stage-for-phase-3-development-of-bleximenib-plus-73-in-amlPromising Phase 1b Results Set Stage for Phase 3 ...
Further exploration of bleximenib plus 7+3 IC has been rationalized by achievement of a 95.8% overall response rate among the 24 patients from ...
4.
aml-hub.com
aml-hub.com/medical-information/menin-inhibitors-for-aml-current-status-and-insights-from-ash-2024Menin inhibitors for AML: Current status and insights from ASH ...
In the 21 patients included in the efficacy set, the overall response rate (ORR) was 95%, with 86% achieving composite complete remission (CRc: ...
Bleximenib, an investigational selective menin inhibitor ...
At the recommended Phase 2 dose (RP2D), patients with relapsed or refractory AML achieved an overall response rate (ORR) of 82 percent and a ...
Clinical Integration of Menin Inhibitors in AML - PMC - NIH
The interim data for ziftomenib combined with venetoclax + azacitidine at a dose of 200 mg reported a composite complete remission (CRc) rate of 80% in NPM1m ...
7.
clinical-lymphoma-myeloma-leukemia.com
clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(25)01663-5/fulltextAML-412: Bleximenib Dose Optimization and ...
Bleximenib RP2D was determined at 100 mg BID (after a 50-mg BID step-up dose) with optimal safety, pharmacokinetic exposure, pharmacodynamic response, and ...
8.
ascopost.com
ascopost.com/issues/february-25-2025/novel-menin-inhibitors-show-safety-and-activity-in-several-clinical-trials/Novel Menin Inhibitors Show Safety and Activity in Several ...
The recently approved menin inhibitor revumenib is poised to improve the treatment of acute myeloid leukemia (AML), specifically for disease with a KMT2A ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.